RH5.1-CyRPA-Ripr antigen combination vaccine shows little improvement over RH5.1 in a preclinical setting

RH5.1-CyRPA-Ripr antigen combination vaccine shows little improvement over RH5.1 in a preclinical setting

BackgroundRH5 is the leading vaccine candidate for the Plasmodium falciparum blood stage and has shown impact on parasite growth in the blood in a human clinical trial. RH5 binds to Ripr and CyRPA at the apical end of the invasive merozoite form, and this complex, designated RCR, is essential for en...

Disgrifiad llawn

Manylion Llyfryddiaeth
Prif Awduron: Julie Healer, Jennifer K. Thompson, Karen L. Mackwell, Cecille D. Browne, Benjamin A. Seager, Anna Ngo, Kym N. Lowes, Sarah E. Silk, David Pulido, Lloyd D. W. King, Jayne M. Christen, Amy R. Noe, Vinayaka Kotraiah, Paul J. Masendycz, Rajkannan Rajagopalan, Leanne Lucas, Marianne M. Stanford, Lorraine Soisson, Carter Diggs, Robin Miller, Susan Youll, Kaye Wycherley, Simon J. Draper, Alan F. Cowman
Fformat: Erthygl
Iaith:English
Cyhoeddwyd: Frontiers Media S.A. 2022-12-01
Cyfres:Frontiers in Cellular and Infection Microbiology
Pynciau:
malaria
Plasmodium falciparum
RH5 complex
vaccine
merozoite invasion
Ripr
Mynediad Ar-lein:https://www.frontiersin.org/articles/10.3389/fcimb.2022.1049065/full

Rhyngrwyd

https://www.frontiersin.org/articles/10.3389/fcimb.2022.1049065/full

Eitemau Tebyg